Literature DB >> 21089115

Prediction of long-term survival in chronic heart failure by multiple biomarker assessment: a 15-year prospective follow-up study.

Massimo Volpe1, Pietro Francia, Giuliano Tocci, Speranza Rubattu, Sara Cangianiello, Maria Assunta Elena Rao, Bruno Trimarco, Mario Condorelli.   

Abstract

BACKGROUND: In chronic heart failure (CHF), several plasma biomarkers identify subjects at risk of death over the midterm. However, their long-term predictive value in the context of other candidate predictors has never been assessed. This information may prove valuable in the management of a chronic disease with a long natural history, as CHF is today. HYPOTHESIS: We aimed to assess the very-long-term prognostic power of a set of biomarkers to identify CHF patients at highest risk for all-cause mortality.
METHODS: A group of 106 consecutive outpatients with CHF (85 male and 21 female, median age 56 y) was followed for 15 years. Echocardiographic tracings and blood samples were collected at study entry to evaluate cardiac function, plasma atrial natriuretic peptide (ANP), aldosterone, and erythropoietin, and plasma renin activity. The relationships between biomarkers, clinical and echocardiographic variables, and mortality were assessed.
RESULTS: After 15 years, 86 of the 106 patients (81%) had died. Multivariate analysis showed that ANP was the best independent predictor of survival over several clinical, echocardiographic, and humoral variables (hazard ratio: 5.62, 95% confidence interval: 3.37-9.39, P < 0.001 for plasma levels < median value of 71 pg/mL). Plasma renin activity and erythropoietin provided prognostic information in univariate analysis, but lost their predictive power when adjusted for covariates.
CONCLUSIONS: The present study represents the longest available follow-up of patients with CHF evaluating the prognostic power of multiple biomarkers. It shows that a simple assessment of plasma ANP levels is the strongest long-term predictor of death in all stages of heart failure.
Copyright © 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21089115      PMCID: PMC6653128          DOI: 10.1002/clc.20813

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  38 in total

Review 1.  Hormones and hemodynamics in heart failure.

Authors:  R W Schrier; W T Abraham
Journal:  N Engl J Med       Date:  1999-08-19       Impact factor: 91.245

2.  Direct comparison between endothelin-1, N-terminal proatrial natriuretic factor, and brain natriuretic peptide as prognostic markers of survival in congestive heart failure.

Authors:  P L Selvais; A Robert; S Ahn; F van Linden; J M Ketelslegers; H Pouleur; M F Rousseau
Journal:  J Card Fail       Date:  2000-09       Impact factor: 5.712

3.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

4.  Long-term trends in the incidence of and survival with heart failure.

Authors:  Daniel Levy; Satish Kenchaiah; Martin G Larson; Emelia J Benjamin; Michelle J Kupka; Kalon K L Ho; Joanne M Murabito; Ramachandran S Vasan
Journal:  N Engl J Med       Date:  2002-10-31       Impact factor: 91.245

5.  Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995.

Authors:  K MacIntyre; S Capewell; S Stewart; J W Chalmers; J Boyd; A Finlayson; A Redpath; J P Pell; J J McMurray
Journal:  Circulation       Date:  2000-09-05       Impact factor: 29.690

6.  Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction.

Authors:  B Stanek; B Frey; M Hülsmann; R Berger; B Sturm; J Strametz-Juranek; J Bergler-Klein; P Moser; A Bojic; E Hartter; R Pacher
Journal:  J Am Coll Cardiol       Date:  2001-08       Impact factor: 24.094

7.  Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure.

Authors:  M Hülsmann; R Berger; B Sturm; A Bojic; W Woloszczuk; J Bergler-Klein; R Pacher
Journal:  Eur Heart J       Date:  2002-06       Impact factor: 29.983

8.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

Authors: 
Journal:  Lancet       Date:  1999-06-12       Impact factor: 79.321

9.  B-type natriuretic peptide predicts sudden death in patients with chronic heart failure.

Authors:  Rudolf Berger; Martin Huelsman; Karin Strecker; Anja Bojic; Petra Moser; Brigitte Stanek; Richard Pacher
Journal:  Circulation       Date:  2002-05-21       Impact factor: 29.690

10.  Differential regulation of atrial and brain natriuretic peptides and its implications for the management of left ventricular volume overload.

Authors:  N Dzimiri; A Moorji; B Afrane; Z Al-Halees
Journal:  Eur J Clin Invest       Date:  2002-08       Impact factor: 4.686

View more
  10 in total

1.  Higher plasma levels of MR-pro-atrial natriuretic peptide are linked to less anxiety: results from the observational DIAST-CHF study.

Authors:  Thomas Meyer; Christoph Herrrmann-Lingen; Mira-Lynn Chavanon; Kathleen Nolte; Caroline Anna Pasedach; Lutz Binder; Burkert Pieske; Gerd Hasenfuss; Rolf Wachter; Frank Edelmann
Journal:  Clin Res Cardiol       Date:  2015-02-10       Impact factor: 5.460

Review 2.  Natriuretic peptides in cardiovascular diseases: current use and perspectives.

Authors:  Massimo Volpe; Speranza Rubattu; John Burnett
Journal:  Eur Heart J       Date:  2013-11-13       Impact factor: 29.983

Review 3.  Secreted proteins as a fundamental source for biomarker discovery.

Authors:  Miroslava Stastna; Jennifer E Van Eyk
Journal:  Proteomics       Date:  2012-01-19       Impact factor: 3.984

Review 4.  A real-world perspective on the prevalence and treatment of heart failure with a reduced ejection fraction but no specific or only mild symptoms.

Authors:  Farzin Beygui; Manuel Anguita; Ulrich Tebbe; Josep Comin-Colet; Michel Galinier; Peter Bramlage; Eva Turgonyi; Katharina Lins; Lynda Imekraz; Trinidad de Frutos; Michael Böhm
Journal:  Heart Fail Rev       Date:  2015-09       Impact factor: 4.214

Review 5.  Atrial natriuretic peptide in cardiovascular biology and disease (NPPA).

Authors:  Wei Song; Hao Wang; Qingyu Wu
Journal:  Gene       Date:  2015-06-12       Impact factor: 3.688

6.  Percutaneous Closure of Left Atrial Appendage affects Mid-Term Release of MR-proANP.

Authors:  Michael Behnes; Benjamin Sartorius; Annika Wenke; Siegfried Lang; Ursula Hoffmann; Christian Fastner; Martin Borggrefe; Thomas Roth; Jakob Triebel; Thomas Bertsch; Ibrahim Akin
Journal:  Sci Rep       Date:  2017-08-22       Impact factor: 4.379

7.  Etiology-specific assessment of predictors of long-term survival in chronic systolic heart failure.

Authors:  Jennifer Franke; Christian Zugck; Matthias Hochadel; Anna Hack; Lutz Frankenstein; Jingting Désirée Zhao; Philipp Ehlermann; Manfred Nelles; Uwe Zeymer; Ralph Winkler; Ralf Zahn; Hugo A Katus; Jochen Senges
Journal:  Int J Cardiol Heart Vasc       Date:  2015-02-26

Review 8.  Resetting the neurohormonal balance in heart failure (HF): the relevance of the natriuretic peptide (NP) system to the clinical management of patients with HF.

Authors:  Speranza Rubattu; Filippos Triposkiadis
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

Review 9.  Transient Receptor Potential Channels, Natriuretic Peptides, and Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure.

Authors:  Kun Ding; Yang Gui; Xu Hou; Lifang Ye; Lihong Wang
Journal:  Front Cardiovasc Med       Date:  2022-05-26

Review 10.  Effect of lower sodium intake on health: systematic review and meta-analyses.

Authors:  Nancy J Aburto; Anna Ziolkovska; Lee Hooper; Paul Elliott; Francesco P Cappuccio; Joerg J Meerpohl
Journal:  BMJ       Date:  2013-04-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.